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Growth phenotype of cultured skin fibroblasts from IDDM patients
with and without nephropathy and overactivity of the Na'/H antiporter.
An increased activity of the Na'7H antiporter in cells from patients with
insulin-dependent diabetes mellitus (IDDM) has been proposed as a
potential marker of nephropathy. We evaluated Na '/H antiporter
activity and its relationship to DNA and protein synthesis in cultured skin
fibroblasts from patients with IDDM classified as having either overt
nephropathy or absence of nephropathy on the basis of urinary albumin
excretion and kidney biopsy findings. In IDDM patients with overt
ncphropathy, Na7HF antiporter activity in serum stimulated cells was
increased as compared to cells from control subjects (9.62 0.89 vs.
5.67 0.97 mmol H'7min, P < 0.005, respectively) and cells from IDDM
patients without nephropathy (7.22 0.67 mmol H/min, P < 0.025). By
contrast, in cells made quiescent by serum deprivation Na' IH' antiporter
activity was lower than in serum-stimulated cells and there were no
significant differences between the three groups. DNA synthesis assessed
by [3H] thymidine incorporation was increased in the IDDM group with
nephropathy as compared to the group without nephropathy (138 14 vs.
105 13 cpm/1000 cells, respectively, P < 0.05) and as compared to
control subjects (65 11 cpm/1000 cells, P < 0.001). By contrast, protein
synthesis assessed by ['4C] L-leucine incorporation was not increased in
fibroblasts from IDDM patients with ncphropathy, suggesting that cellular
hypertrophy is not a feature of their altered growth phenotype. After
chronic inhibition of the Na/H antiporter using EIPA (25 jLM), [3H]
thymidine incorporation was reduced by about 20% both in cells from
IDDM patients and controls. This parameter therefore remained higher in
cells from IDDM patients with nephropathy than in those from controls
(81 16 vs. 40 6 cpm/1000 cells, P < 0.05), while in cells from IDDM
patients without nephropathy [3H] thymidine incorporation after EIPA
(56 7.0 cpm/l000 cells) was intermediate between cells from controls
and IDDM patients with nephropathy. We argue that cultured skin
fibroblasts from IDDM patients, with nephropathy display an abnormal
growth phenotype characterized by cell hyperplasia. This growth pheno-
type is associated with overactivity of the Na /H antiporter during serum
stimulation but not when cells arc made quiescent and persists after
inhibition of the Na/H' antiporter. Our data, therefore, further shows
that overactivity of the Na '/H antiporter is not required for the
expression of the altered growth phenotype of cultured skin fibroblasts
from IDDM patients with ncphropathy.
The development of diabetic nephropathy is the strongest
predictor of premature death and cardiovascular disease in insu-
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lin-dependent diabetic patients (IDDM) [1]. Overt diabetic ne-
phropathy occurs in about 25% of patients with insulin-dependent
diabetes mellitus [2, 31, although the prevalence of this complica-
tion seems to be declining [4]. The risk for nephropathy in IDDM
patients appears, at least in part, to be genetically determined [5,
6]. This is apparent from the findings that nephropathy develops
in some patients with IDDM despite good glycemic control and
that a substantial proportion of patients in poor control escape
diabetic nephropathy [7—9]. Identification of those patients sus-
ceptible to develop nephropathy is therefore a priority in diabetes
research.
Factors that have been suggested as determinants of risk for
diabetic nephropathy include familial history of diabetic nephrop-
athy [5, 8], family history of hypertension [9], and elevated rates of
erythrocyte Na/Li countertransport [9, 10]. Recent studies by
Viberti and his collaborators have shown an increase in the
activity of the Na/H antiporter [11, 12] as well as intrinsic
growth abnormalities in cultured skin fibroblasts from patients
with Type I diabetes with nephropathy [12]. These authors have
therefore proposed that overactivity of the Na' /H antiporter in
skin fibroblasts may be a marker of diabetic nephropathy in
IDDM patients. The Na '/H antiporter consists of a family of
related isoforms, each a product of a separate gene [13-161. The
NHE-1 isoform is ubiquitously expressed in the plasma membrane
of mammalian cells where it regulates cell volume, intracellular
pH (pH,) and cell growth [17—19].
On the basis of the foregoing observations, overactivity of the
Na/H antiporter has been suggested as a possible cause of
increased growth in cultured fibroblasts from IDDM patients with
nephropathy [121 and in cultured vascular smooth muscle cells
from the spontaneously hypertensive rat [20]. The objective of this
study was to examine Na/H antiporter activity and its relation-
ship to cell growth in patients with IDDM using skin fibroblasts in
culture as an in vitro model. Na'7H antiporter activity was
assessed in cells made quiescent by serum deprivation and in cells
stimulated by exposure to serum. The latter condition was used as
an approach to examine the impact of stimulation of growth by
serum on Na'7H' antiporter activity. We further investigated if
alterations in cell growth in cultured skin fibroblasts from IDDM
patients are secondary to Na'7H antiporter overactivity by
investigating cell growth in the face of Na/H antiporter inhibi-
tion using a specific inhibitor, ethyl-isopropylamiloride (EIPA).
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Studies were performed in IDDM patients with and without
nephropathy to ascertain whether or not the latter patients display
a distinctive growth phenotype and whether or not it is related to
Na/H antiporter overactivity.
Methods
Patients
Eighteen Caucasian IDDM patients and 8 age-matched normal
subjects were studied. Patients enrolled in a study of the natural
history of diabetic nephropathy at the University of Minnesota
participated in these studies. All studies were approved by the
Committee on the Use of Human Subjects in Research. Clinical
studies including all renal function studies were carried out during
a one week admission to the Clinical Research Center (CRC). A
percutaneous kidney biopsy was performed under ultrasound
guidance in all patients and renal tissue was immediately pro-
cessed for light and electron microscopy. Morphometric measure-
ments were performed by a single observer (PR), unaware of the
patients' identities. Those consisted in estimations of mesangial
fractional volume [Vv(mes!glom)] and glomerular basement
membrane (GBM) width as previously described [21]. IDDM
patients were divided into two subgroups on the basis of their
albumin excretion rates (UAE). Those excreting more than 200
Lg/min were classified as having overt nephropathy (N = 9), while
those excreting less than 20 jig/mm (normoalbuminuric, N = 9)
were classified as having no evidence of renal involvement [11, 12,
221. Eight of the patients with overt nephropathy were being
treated with antihypertensive medications including hydralazine
(1 patient), verapamil (1 patient), furosemide and enalapril (1
patient), captopril and spironolactone (1 patient), enalapril and
nifedipine (1 patient), metalazone, enalapril and diltiazem (1
patient) and furosemide alone (2 patients).
In all the IDDM patients the known duration of the disease was
at least 10 years. IDDM patients with an average of 16 years of
disease duration such as those in this study (range 10 to 24 years),
are generally considered to be at low risk of diabetic nephropathy
if UAE is normal [231. In IDDM patients with high UAE rates,
kidney biopsies revealed typical changes of advanced diabetic
nephropathy [21]. Accordingly, structural abnormalities were not
further assessed by morphometric analysis. Morphometric data
from kidney biopsies of normoalbuminuric patients are given
under results. Since microalbuminuria develops in IDDM before
the onset of clinically overt nephropathy [22], and is regularly
associated with established renal lesions [24], we excluded pa-
tients with microalbuminuria from this study that was aimed at
studying IDDM patients without evidence of functional nephrop-
athy (albuminuria) as well as absent structural evidence of ne-
phropathy as compared to IDDM patients with established ne-
phropathy.
Urinary albumin excretion was measured using a specific flu-
orometric immunoassay in three separate urine samples each
collected over 24 hours and expressed as jig/mm [251. Glomerular
filtration rate (GFR) was estimated from the three 24-hour
measures of clearance of endogenous creatinine performed in the
CRC. Glycosylated hemoglobin (Hb Ale) was determined by high
performance liquid chromatography.
Skin fibroblasts were obtained using a standard 4 mm skin
punch biopsy, as routinely employed for diagnosis in dermatology.
Biopsies were taken from the costo vertebral angle of the back at
the site already anesthesized for kidney biopsy in the IDDM
patients and at parallel sites in the controls. Cells were dispersed
with a forceps and grown in culture. Cells, frozen in liquid
nitrogen, were then shipped to the Lake Side VA Medical
Sciences Building (Chicago, IL, USA) where all the cell studies
were performed. Cultures were fed or passaged twice weekly with
Dulbecco's modified Eagle's medium, supplemented with Ham's
Fl2 nutrient (DME-F12), 10% fetal calf serum, penicillin (100
U/mi), streptomycin (100 jig/mi) and fungizone (250 jig/mI) at
37°C in a humidified atmosphere with 95% air—5% CO2. The
glucose concentration of this medium is 17.9 m. Only subcul-
tures of fIbroblasts in early subpassage in culture (between the 2nd
and 9th passages) were used for the studies described below. The
in vitro assays described below were carried out by one of us (A.L.)
without knowledge of the specific source of the fibroblasts (IDDM
patients vs. controls).
Measurement of intracellular pH and Na /H antiporter activity
Intracellular pH (pH) and Nat'H antiporter activity were
determined in fibrobiasts under two different culture conditions,
namely serum deprivation and serum stimulation. In the first
condition, fibroblasts cultures were grown to near confluence and
made quiescent by the removal of 10% fetal calf serum (FCS)
from the media for a period of 24 hours. For protocols utilizing
serum, 10% FCS was re-added for 24 hours to cultures that had
been previously serum deprived for 24 hours. Throughout this
time cells were kept in a HCO3/C02 media (HCO3 16 mEq/liter,
5% CO2—95% air). About one hour prior to pH assays, cells were
transferred to a HCO3-free solution buffered with HEPES (pH
7.4) with the following composition (mM): NaC1 133.8, KC1 4.7,
CaCI7 1.25, MgCI2 1.25, NaHPO4 0.97, NaH2PO4 0.23, glucose 5,
HEPES 5.
The pH sensitive fluorescent probe, 2", 7" bis (carhoxyethyl)-5,-
6-carboxyfluorescein (BCECF) was used to measure pHi as
previously described [26—28]. On the day of the study, skin
fibroblasts were loaded with 1 jig/mI BCECF-AM (molecular
probes) for 30 minutes at 37°C. The coverslips were washed three
times with the assay buffer and allowed to sit 30 minutes at room
temperature to stabilize before proceeding. BCECF fluorescence
was measured at excitation wavelengths of 500 and 440 am and an
emission wavelength of 530 nm using a Perkin-Elmer LS-5
spectrofluorometer connected to an IBM PC-XT. The computer
was programmed to rapidly alternate the two excitation wave-
lengths while constantly recording the emission wavelength. Cal-
ibration of the 500/440 nm ratio to pHi was done at the beginning
of each experiment using 6 jig/mi nigericin in 120 mrvi KCI
solution [28].
At the start of the experiment, a coverslip was placed in a
customized holder and inserted into a suction cuvette (Helma)
resting in a water jacketed cuvette holder. The temperature was
maintained at a constant 37°C. The coverslips were superfused at
a rate of 2 mI/mm with the prewarmed assay buffer using a 50 ml
syringe inserted in a Sage infusion pump. The contribution of
external BCECF due to dye leakage was found to be negligible at
this rate of superfusion as demonstrated by the lack of the
fluorescence in the effluent. When experimental solutions were
switched during the course of an experimental maneuver, the rate
was increased to 10 mi/mm for 30 seconds to enhance the rate of
exchange. At this rate there is > 95% exchange of solutions within
20 seconds. For the baseline pH1 reported, we defined each N as
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the average pH1 for the day (usually 4 coverslips). That is, we
treated each coverslip from the same cell line assayed on the same
day as a repeat measure, rather than an independent measure.
Therefore, each N is the average of triplicate or quadruplicate
measurements.
For experiments examining Na7H antiporter activity, skin
fibroblasts were acid loaded to a pH1 of about 6.50 using the
NH4C1 washout technique [28]. The application and subsequent
removal of 15 m of NH4C1 in the superfusion solution causes
pH to decrease rapidly after an initial alkalization [26]. In the
presence of a buffer solution containing 145 m of Na, a rapid
recovery of pH ensues [28]. Addition of ELPA (either 1.25 /.LM or
25 /LM) to the superfusate completely obliterates the rate of pH1
recovery from intracellular acidification [28]. Stimulated Na 7H
antiporter activity was therefore taken as the initial rate of pHi
recovery (pH1/t during the first minute of recovery) [28].
H efflux was determined as pH1/min X intrinsic buffering
power (B) at the cells. B was determined by pulsing the cells with
2.5 mrvl NH4C1 and measuring the change in pH1 seen at 20
seconds [29]. The buffering power was calculated as zNH4/pH1.
The concentration of (NH4] was calculated using a pK of 9.21
and assuming that NH3 is in equilibrium across the cell membrane
[28, 291.
Cell growth studies
Skin fibroblasts were transferred into six well plates at a density
of 5 x io cells per well for the study of cell growth. The following
morning, the medium was changed to a serum free medium for 24
hours to synchronize the cells in G0 growth phase. Removal of
serum did not affect cell attachment and had no discernable effect
on cell morphology or the cells ability to exclude trypan blue.
Twenty-four hours later, the cells in one well were harvested with
trypsin-EDTA and counted using a Coulter Counter (ZM). The
medium of the remaining five wells was changed to DME-F12
(glucose concentration 17.9 mM) containing 10% FCS with 1
j.Ci/ml [3H] thymidine and 100 j.Ci/ml [14C] L-leucine added to
study DNA and protein synthesis, respectively [28, 30]. After 24
hours the medium was aspirated and cells were washed three
times with PBS, fixed by washing twice with ice-cold 10% TCA,
washed twice with 95% ethanol, and extracted with 0.1 M NaOH
for 60 minutes [28]. Aliquots were counted in a liquid scintillation
counter. Results are expressed as CPM/1000 cells. Cell total
protein was determined by the method of Bradford [31].
To determine the effect of inhibition of the Na/H antiporter
on these growth parameters, EIPA (25 1M) was added to DME-
F12 medium containing 10% FCS. After 24 hours of exposure to
EIPA, DNA and protein synthesis were evaluated using [3H]
thymidine incorporation and [14C1 L-leucine, respectively, as
described above.
Statistics
All data arc presented as mean SE. Statistical differences
between three groups were sought using a one-way ANOVA.
Differences between two groups were determined using a Stu-
dent's 1-test for paired or unpaired data, as appropriate. Differ-
ences in the pH1 recovery rates over time between groups were
determined by a two-way ANOVA. Differences were considered
statistically significant when P < 0.05.
Table 1. Clinical data
Controls
IDDM without
nephropathy
IDDM with
nephropathy
Number 8 9 9
Sex (male/female) 4/4 6/3 2/7
Age years 33 3 32 2 37 3
range 24—50 21—41 24—49
Albumin excretion pg/mm — 6.7 7.9 979 292*
range (4.2—13.4) 200—2704
Disease duration years — 16 2 23 2*
range 10—24 13—33
Mean blood pressure mm Hg — 114/72 123/77
Hb Ale % — 8.4 0.4 10.3 0.8*
range 5.6—9.6 7.3—15
GFR ml/min/173 m2 — 124 5 70 7*
range 102—153 43—113
Vv (mes/glom) — 0.22 0.01 —
range 0.17—0.26
GBM width nm — 455 31 —
range 325—609
Data arc mean SE. Abbreviations are: Vv, mesangial fractional
volume; GBM, glomerular baseline membrane; GFR, glomerular filtra-
tion rate.
Statistically significant difference (P < 0.05) between IDDM patients
with and without nephropathy
Results
Clinical data
Data from all subjects are summarized in Table 1. In IDDM
patients with overt nephropathy glomerular filtration rate, mea-
sured as creatinine clearance, was moderately reduced (70 7
ml/min/1.73 m2; N = 9) and kidney biopsies revealed typical
lesions of advanced diabetic nephropathy [21]. In the subgroup of
IDDM patients with a urinary albumin excretion (UAE) less than
20 j.g/min (N = 9), creatinine clearance was 124 5 ml/min/1.73
m2 (normal range 90 to 125 ml!min/1.73 m2). In these normoalbu-
minuric patients, morphometric analysis revealed a mesangial
fractional volume (Vv mes/glom) of 0.22 0.03, and a GBM
width of 455 94 nm. Five of the nine normoalbuminuric
patients, had values for GBM width above the normal range while
fractional mesangial volume in all patients was within the range
previously reported for normal subjects [21]. Mesangial fractional
volume is the structural index that correlates best with functional
parameters in IDDM patients [21, 23]. Accordingly, normoalbu-
minuric patients entered into this study could be considered to
have little or no renal involvement on the basis of this structural
criteria. Duration of diabetes was longer by seven years in the
group of diabetics with nephropathy than in those classified as
having no evidence of nephropathy. Therefore, one cannot be
certain that some of our patients classified as "without nephrop-
athy" might eventually develop renal involvement although this is
unlikely given an average of 16 years of IDDM duration (range 10
to 24 years).
Age was not significantly different between the two subgroups
of IDDM patients. Mean blood pressure was not significantly
different between the two groups (Table 1). However, 8 of the 9
patients with nephropathy were hypertensive and were taking
antihypertensive medications (Methods). All patients in the group
without nephropathy were normotensive. Glycemic control as
estimated by HbgAlc was poorer in the overt nephropathy group.
Only two of the nine patients with nephropathy, however, had
Lurbe et at: Cell growth and Na7I-L antiporler activity 1687
Fig. 1. Intracellular pH (pH,) at steady-state in fibroblasts from controls(s), IDDM patients with nephropathy () and without nephropathy (iii).
There were no significant differences between the groups either in the
absence of serum or after stimulation with 10% fetal calf serum (FCS).
After exposure to 10% FCS, pH was markedly higher than in its absence
in the three groups (P < 0.001, by unpaired t-test). 0 5 10 15 20 25
Time, minutes
markedly elevated levels of HbAlc (12.4% and 15.4%; normal
range 4.1 to 6.1%).
Steady-state pH,
JDDM patients versus controls. pH, in cells from IDDM patients
exposed to 10% FCS, considered as a group was not significantly
different from that of controls (7.30 0.03 and 7.28 0.05,
respectively). In fibroblasts rendered quiescent by serum depriva-
tion for 24 hours, steady-state pH was also not significantly
different between IDDM patients and controls (7.01 0.03 and
7.03 0.6, respectively).
Subgroup analysis. pH in serum-stimulated fibroblasts from
IDDM patients with nephropathy was higher than that of patients
without nephropathy (7.34 0.04 and 7.24 0.03, respectively)
but this difference did not achieve statistical significance. Steady-
state pI-I in serum-deprived fibroblasts was also not significantly
different between the two diabetic subgroups: 7.02 0.04 and
7.01 0.05 in IDDM patients without nephropathy and IDDM
patients with nephropathy, respectively. pH1 was also not signifi-
cantly different between either group of diabetic patients and
controls when determined in either serum-stimulated or serum-
deprived conditions (Fig. 1).
Steady-state pH1 was higher in cultured fibroblasts studied 24
hours after exposure to 10% FCS than in cells deprived of serum
(Fig. 1). This serum-associated difference in pH1 was seen in cells
from control subjects and in cells from both subgroups of diabetic
patients and reflects stimulation of Na/H antiporter activity by
exposure to serum.
Na /H antiporter activity
JDDM patients versus controls. Serum-stimulated or serum-
deprived fibroblasts were acidified using the NH4C1 washout
technique to evaluate Na/H antiporter activity in response to
stimulation by cell acidification [26—291. The pH, achieved by this
procedure was similar in fibroblasts from controls and IDDM
Fig. 2. Na'7H antiporter activity evaluated during pH, recovely from an
acute cell acidification (NH4Clprepulse technique). Only the recovery phase
from pH1 6.5 is shown. Cells from IDDM patients and from controls
exposed to 10% FCS (triangles) had a faster rate of pHi recovery than
cells from IDDM patients and controls kept in serum free media (circles)
(P < 0.01 for both groups by two-way ANOVA). Addition of EIPA at the
end of the recovery caused a significant fall in pH in fibroblasts from both
IDDM patients and control subjects that had been subjected to stimula-
tion with 10% FCS (P < 0.01),but had only a marginal effect on cells from
both groups which had been maintained in the absence of serum. In the
presence of 10% FCS. pH recovery was faster in fibroblasts from IDDM
patients (closed triangles) than in those from control subjects (open
triangles) (P < 0.001 by two way ANOVA). In contrast, in cells main-
tained in the absence of serum, there was no significant difference in the
pH recovery between fibroblasts from TDDM patients (closed circles) and
controls (open circles).
patients assayed in the presence of serum (6.50 0.06 vs. 6.51
0.03, respectively) and, in cells assayed in the absence of serum
(6.41 0.04 vs. 6.41 0.02, respectively). pH, recovery from cell
acidification was rapid in the first minute and essentially complete
after 10 minutes (Fig. 2). In serum-deprived cells the rate of pHi
recovery was slower than in those exposed to 10% FCS. This was
the ease for cells from both IDDM patients and control subjects
(Fig. 2).
In serum-treated fibroblasts from IDDM patients, the initial
rate of pH recovery was faster than in cells from control subjects
(P < 0.01) (Fig. 2). When expressed as H efflux the stimulated
activity of the Na1 IH antiporter was higher in serum-treated
fibroblasts from IDDM patients than in cells from control subjects
(8.47 0.61 and 5.67 0.97 mrvi H/min, respectively, P < 0.01).
By contrast, the initial rate of pH1 recovery from cell acidification
was not significantly different between serum-deprived fibroblasts
from IDDM patients and controls (Fig. 2). Since there were no
significant differences in buffering capacity at an acidic pH1, the
stimulated activity of the antiporter, expressed as H flux, was
also similar between serum-deprived fibroblasts from IDDM
7.4
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7.2
7.0
6.9
6.8
El PA
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7.6
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pared to controls (7715 1020 vs. 3267 889 cpm/well, P <S 0.05). Data at 6, 12, and 24 hours of exposure to 10% FCS are
shown under subgroup analysis (see below).
When expressed as [3HJ thymidine incorporation per cell count,S DNA synthesis at 24 hours of exposure to 10% FCS was about
twofold higher in cells from IDDM patients than in cells from
control subjects (122 9 and 65 11 cpm/1 000 cells, P < 0.005,4 respectively). In contrast, no significant differences in ['4C1 L-
• leucine incorporation, measured concurrently with [3H]-thymi-
dine incorporation, were found between skin fibroblasts from
IDDM patients and control subjects (35 4 and 31 4 cpm/1000
• cells, respectively). Total protein content was also not significantly
different between fibroblasts from IDDM patients and non-
diabetic subjects (0.41 0.04 and 0.42 0.10 jig protein!1000
cells, respectively).
Subgroup analysis. Data on protein content, [14C] L-leucine
incorporation, and [3H1 thymidine incorporation per well in
fibroblasts from controls and from the two sub-groups of IDDM
patients are shown in Figure 4. Stimulation with 10% FCS
induced an increase in total protein content per well over time in
the three groups (P < 0.005 by two-way ANOVA). In cells from
controls, the increase in total protein content per well was
significant only after 24 hours of exposure to 10% FCS while in
cells from both groups of IDDM patients an increase was already
apparent at 12 hours. No significant differences between the three
groups were observed at any of the time points studied (Fig. 4C).
['4C] L-leucine incorporation per well also increased in cells
from the three groups in response to exposure to 10% FCS (Fig.
4B). No significant differences were found between any of the
three groups at any of the time points studied. By contrast, [3H]
thymidine incorporation per well increased to a greater extent in
fibroblasts from IDDM patients with nephropathy than in fibro-
blasts from IDDM patients without nephropathy or in fibroblasts
from control subjects at both 12 and 24 hours after stimulation
with 10% FCS (Fig. 4A). Comparison of the three groups by a
two-way ANOVA indicated that the increase in [3H] thymidine
incorporation was greater in fibroblasts from IDDM with ne-
phropathy than in IDDM patients without nephropathy (P <
0.005) and in those from controls (P < 0.001). Fibroblasts from
IDDM patients without nephropathy also had a greater increase
in thymidine incorporation than controls (P < 0.05). Individual
data points from cells from each subject studied 24 hours after
exposure to 10% FCS are shown in Figure 5A.
Data on [3HJ thymidine and [14CJL-leucine incorporations were
also normalized per cell count. After 24 hours of exposure to 10%
FCS, fibroblasts from IDDM patients with nephropathy had
increased 3H] thymidine incorporation as compared to IDDM
patients without nephropathy (138 14 cpm/1000 cells and 105
13 cpm/1000 cells, respectively P < 0.05). In cells from TDDM
patients without nephropathy [3H] thymidine incorporation was
higher than in cells from controls (65 11 cpm/1000 cells, P <
0.025). Protein synthesis, assessed by '4CI L-leucine incorpora-
tion at 24 hours of exposure to 10% FCS, was not significantly
different between the three subgroups: IDDM patients with
nephropathy (33 5 cpm/1000 cells), without nephropathy (37
5 cpm/1000 cells), and controls (31 4 cpm/1000 cells) (Fig. SB
shows individual data points). Total protein content at 24 hours of
exposure to 10% FCS was also not significantly different between
IDDM patients with and without nephropathy (0.39 0.03 and
0.43 0.06 jig protein/bOO cells, respectively). These values were
0
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Fig. 3. Summaiy of data on H flux (mM Himin) via the Na /H
antiporter in cultured skin fibroblasts from controls (open symbols) and
IDDM patients without nephropathy (shaded symbols) and with nephropathy
(closed symbols). A significant difference between the three groups was
found (P < 0.05 by one way ANOVA). There were significant differences
between cells from IDDM patients with and without nephropathy (P <
0.025 by unpaired I-test), and between controls and diabetics with
nephropathy (P < 0.005 by unpaired t-test) while the difference between
controls and IDDM patients without nephropathy did not reach statistical
significance (P < 0.05 by unpaired (-test).
patients and controls (4.6 0.5 and 4.02 0.5 mM H7min,
respectively).
EIPA (1.25 JiM) was added at the end of the pH1 recovery to see
if there was any Na/H activity when pH1 had returned to its
baseline. EIPA had only a marginal effect on pH in serum
deprived cells, whereas in cells exposed to serum, EIPA resulted
in a substantial fall in pH reflecting Na47H antiporter activity
near steady-state pH1. This action of EIPA on pH1 was seen in
serum-stimulated cells from both IDDM patients and control
subjects (Fig. 2).
Subgroup analysis. The rate of pH1 recovery from cell acidifica-
tion was faster in serum-stimulated fibroblasts from IDDM pa-
tients with nephropathy than in those without nephropathy
(0.55 0.6 vs. 0.41 0.04 pH1/min, P < 0.001, respectively).
When expressed as H efflux, Na/H antiporter activity in
serum-stimulated fibroblasts was also higher in the IDDM pa-
tients with nephropathy than in those without nephropathy
(9.62 0.89 and 7.22 0.67 mvi H/min, respectively, P < 0.025)
and controls (5.67 0.97 mt H !min, P < 0.005). The stimulated
Na IH antiporter activity in the IDDM patients without ne-
phropathy was intermediate between controls and IDDM patients
with nephropathy (Fig. 3). By contrast, no significant differences
in Na/H+ antiporter activity were found between serum-de-
prived fibroblasts from IDDM patients with nephropathy (3.19
0.58 mM H7min), IDDM patients without nephropathy (4.77
0.79 ms H7min), and control subjects (3.95 0.37 mivi H47min).
IDDM patients versus controls. DNA synthesis, as inferred from
[3H] thymidine incorporation, at 24 hours of exposure to 10%
FCS was increased in fibroblasts from IDDM patients as corn-
Cell growth
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Controls IDDM IDDM
(no (nephropathy)
nephropathy)
(no (nephropathy)
nephropathy)
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Fig. 5. f3JJj thymidine incorporation per well (A) and normalized per
number of cells (B) after 24 hours stimulation with 10% FCS, in fibroblasts
from controls (open symbols), IDDM patients without nephropathy (shaded
symbols) and IDDM patients with nephropathy (closed symbols). Each point
represents one assay from one subject; cell lines were usually assayed
twice. [3H1 thymidine incorporation per well was higher in IDDM patients
with nephropathy than in those without nephropathy (P < 0.002 by
unpaired t-test) and controls (P < 0.005 by unpaired t-test). When
normalized per number of cells (B) [3H1 thymidine incorporation was
higher in IDDM patients with nephropathy than in those without ne-
phropathy (P < 0.05 by unpaired t-test) and controls (P < 0.005 by
unpaired t-test). There was also a significant difference between controls
and IDDM patients without nephropathy (P < 0.025 by unpaired t-test).
Fig. 4. /3HJ thymidine incorporation (4), f'4J L-leucine incorporation
(B) and total protein content (C) per well, in fibroblasts from controls (0),
IDDIvI patients without nephropathy (A) and JDDM patients with nephrop-
athy (S) after 6, 12 and 24 hours after stimulation with 10% FCS. All three
growth parameters increased in the three groups over time as determined
by a two-way ANOVA: [3H] thymidine incorporation P < 0.001, '4C1
L-leucinc incorporation P < 0.001, and total protein content I' < t).005. At
12 hours, [3H thymidine incorporation in fibroblasts from IDDM patients
without nephropathy was lower than in fibroblasts from TDDM patients
with nephropathy (P < 0.05) and higher than in controls (P < 0.05). At 24
hours, [111 thymidine incorporation in fibroblasts from IDDM patients
without nephropathy was lower than in fibroblasts from TDDM patients
with nephropathy (P < 0.02). '4C1 L-leucine incorporation and total
protein content per well were not significantly different between the three
groups at any of the time points studied.
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also not significantly different from those of controls subjects
(0.42 0.10 protein/1000 cells).
When expressed per rg protein, [3H] thymidine incorporation
was also increased in fibroblasts from TDDM patients with
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nephropathy as compared to IDDM patients without nephropathy
(409 56 and 256 51 cpm/jsg protein, respectively, P < 0.05)
whereas leucine incorporation was not significantly different be-
tween these two groups (73 11 and 64 12 cpm/jsg protein,
respectively).
E/fect of EJPA on growth and Na /H antiporter activity
JDDM patients versus controls. In cells from control subjects,
EIPA (25 flM) inhibited [3H] thymidine incorporation by 20% as
compared to cells simultaneously studied in the absence of EIPA
(54 9 and 40 6 cpm/1 000 cells, respectively, P < 0.05). In cells
from IDDM patients EIPA inhibited [3H] thymidine incorpora-
tion by 21% (94 11 and 70 10 cpm/l000 cells, with and
without EIPA, respectively, P < 0.05). Since the percent inhibi-
tion was similar in cells from controls subjects and IDDM
patients, the pre-existing differences in [3HJ thymidine incorpora-
tion between the two groups persisted in the presence of EIPA.
That is, in the presence of EIPA, fibroblasts from IDDM patients
had a higher rate of [3H1 thymidine incorporation than those from
control subjects (70 10 and 40 6 cpm/l000 cells, respectively,
P < 0.05).
EIPA (25 /.LM) did not inhibit ['4C] L-leucine incorporation
significantly in either fibroblasts from normal subjects (39 6 and
36 10 cpm/1000 cells with and without EIPA, respectively) or
IDDM patients (32 4 and 37 8.0 cpm/1000 cells with and
without EIPA, respectively).
An additional set of experiments examined the pH recovery
from an acid load in cells that had been incubated with E1PA for
24 hours to determine whether or not Na47H4 antiporter activity
had been effectively inhibited by chronic exposure to this inhibi-
tor. Steady-state pH, was lower in cells preincubated with EIPA
(25 /.LM) than control cells that had not undergone EIPA prein-
cubation (7.08 0.03 vs. 7.21 0.03, P < 0.05, respectively). This
finding indicates that the Na/H antiporter was effectively
inhibited during incubation with EIPA. Moreover, in cells prein-
cubated with EIPA the rate of pH1 recovery from acute cell
acidification was markedly decreassed as compared to cells not
incubated with EIPA (0.05 0.01 vs. 0.18 0.02 pH units/i mm,
P < 0.01, respectively).
Subgroup analysis. After incubation with EIPA (25 /.tM), a
significant difference in [3H] thymidine incorporation was found
between fibroblasts from IDDM patients with nephropathy and
control subjects (81 16 and 40 6 cpm/1000 cells, respectively,
P < 0.05). In cells from IDDM patients without nephropathy, [3H]
thymidine incorporation (56 7 cpm/1000 cells) was intermediate
between controls and IDDM patients with nephropathy.
After incubation with EIPA (25 fLM) ['4C] L-leucine incorpo-
ration was not significantly different between fibroblasts from
IDDM patients with nephropathy and controls (30 6 and 39
6 cpm/1000 cells) or between fibroblasts from IDDM patients with
and without nephropathy (30 6 and 33 5 cpm/1000 cells).
Discussion
This study shows that, after exposure to serum, cultured skin
fibroblasts from IDDM patients with nephropathy have enhanced
activity of the Na/H antiporter, as well as increased DNA
synthesis. A time-dependent increase in protein synthesis in
response to serum stimulation was observed in cells from controls
and TDDM patients with and without nephropathy without signif-
icant differences observed between them. By contrast, the increase
in thymidine incorporation elicited by serum was clearly aug-
mented in cells from IDDM patients with nephropathy as com-
pared to the other two groups (Fig. 4). The findings of a higher
rate of [3H] thymidine incorporation but similar rates of [14C1
L-leucine incorporation and total protein content in cultured skin
fibroblasts from IDDM patients with nephropathy is indicative of
a hyperplastic phenotype. Cell hypertrophy was not evident in
fibroblasts from IDDM patients with or without nephropathy as
inferred from the finding that neither the increase in ['4C1
L-leucine incorporation nor the increase in total protein content
observed after exposure to serum were different from those of
controls.
The hyperplastic growth phenotype identified in this study was
clearly more apparent in cultured skin fibroblasts from IDDM
patients in whom overt nephropathy had developed than in those
in whom this complication had not developed as discerned by
normal urinary albumin excretion rate and renal biopsy (Fig. 4).
Since only a fraction of patients with IDDM develop nephropathy,
[1, 3, 4, 8, 9], the finding of an abnormal growth phenotype
expressed in cultured skin fibroblasts may provide a potential
marker for the development of ncphropathy in IDDM patients.
Studies performed before and after the development of nephrop-
athy would be required to substantiate the validity of this concept.
It should be noted that patients with long-term IDDM and
normal albumin excretion are a relatively heterogeneous popula-
tion in that some patients have normal glomerular structure while
others have quite advanced glomerular lesions, comparable with
those observed in patients with incipient nephropathy defined by
the presence of microalbuminuria [24]. This study is unique in that
we selected IDDM patients without microalbuminuria who, de-
spite long disease duration, did not have glomerular mesangial
expansion in an effort to ensure that they did not have renal
involvement. The findings of intermediate values of Na/H
antiporter activity (Fig. 3) and DNA synthesis (Figs. 4 and 5) in
fibroblasts from such patients as compared to those from normal
subjects and IDDM patients with overt nephropathy may reflect a
predisposition to subtle abnormalities in glomerular mesangial
cells and the microvasculature which may or may not be progres-
sive with time. Consistent with this view, we have observed a
positive correlation of fractional mesangial volume derived from
morphometric analysis from kidney biopsies and [3Hj thymidine
incorporation in skin fibroblasts from IDDM patients without
microalbuminuria (unpublished observation).
A concordance in Na47H antiporter activity in sibling pairs
from IDDM patients with nephropathy has been recently re-
ported using cultured skin fibroblasts [321. These patients are also
concordant for lesions characteristic of diabetic nephropathy [33].
These observations further strengthen the association of diabetic
nephropathy with increased Na/H antiporter activity and in-
creased DNA synthesis in cultured skin fibroblasts and support a
genetic basis for these phenomena. To formally exclude the
possibility that IDDM per se, independently of renal involvement,
is associated with these alterations one would need to study a
randomly selected group of TDDM patients to compare to con-
trols. The finding of a lack of difference in a large sample of such
patients would then rule out an effect of the diabetic state per se
on Na/H antiporter activity and cell growth. We believe that
our data, in samples of IDDM patients selected for the presence
of and the absence of nephropathy, together with previous studies
in IDDM patients [11, 12, 351, support the concept of these
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abnormalities in fibroblasts being a reflection of renal involve-
ment. Additional alterations in the growth phenotype expressed in
cultured fibroblasts from IDDM patients could be present as well.
For example, earlier studies using skin fibroblasts from IDDM
subjects showed a decreased replicative lifespan, consistent with
premature senescence [35, 36], although other studies have not
confirmed this finding [37].
The findings of an increase in both Na/H antiporter activity
and [3HJ thymidine incorporation in cultured skin fibroblasts from
IDDM patients could be interpreted as evidence that increased
DNA synthesis is due to overactivity of the Na/H antiporter or
vice versa. Alternatively, they could he totally unrelated. We
found overactivity of the Na41H antiporter in cultured fibro-
blasts from IDDM patients with nephropathy only under serum-
stimulated conditions (Fig. 2). This, together with the finding that
Na/H antiporter activity was not augmented in fibroblasts from
IDDM patients made quiescent by serum deprivation, suggests
that Na/H antiporter over activity in IDDM patients is related
to serum-stimulated cell growth in culture rather than the oppo-
site (that is, enhanced growth as a result of Na/H antiporter
overactivity). To address this issue, DNA synthesis in cells incu-
bated with EIPA, a specific inhibitor of the Na/H antiporter
was examined. Since it is well known that very small concentra-
tions of EIPA are sufficient to inhibit the NHE-1 isoform of the
Na/H antiporter, the only isoform known to be expressed in
fibroblasts [13, 14], we used this inhibitor at a low concentration
(25 /LM). Incubation with EIPA for 24 hours resulted in a marked
inhibition of the initial pHi recovery from cell acidification, a
process which is largely NaF /H antiporter mediated. This dem-
onstrates effective inhibition of the Na/H antiporter under
conditions similar to those used to assess growth parameters in
the presence of EIPA. The degree of inhibition of DNA synthesis
in these studies was virtually the same in cultured fibroblasts from
IDDM patients with nephropathy, without nephropathy, and
controls. Thus, the pre-existing differences in [3H] thymidine
incorporation (that is, without EIPA) between these groups
persisted after inhibition of the Na/H antiporter. Protein
synthesis assessed by ['4C] L-leucine incorporation, was totally
unaffected by EIPA (25 mM). Our data therefore shows that in
cultured skin fibroblasts, virtually complete inhibition of the
Na11H antiporter with relatively low doses of EIPA inhibits
DNA synthesis only by 20% without inhibiting protein synthesis.
Other studies have also shown that activation of the Na/H
antiporter is not a prerequisite for growth in all cell types [38].
Our finding that in cells from patients with IDDM, DNA synthesis
is augmented in the face of effective Na '/H antiporter inhibi-
tion, show that overactivity of this transport system cannot be the
sole cause of the growth alteration observed in cultured fibroblasts
from such patients.
A cell culture model would be particularly useful as an in vitro
marker for diabetic nephropathy because other influences related
to the metabolic-hormonal milieu prevailing in vivo can be
controlled in vitro. This is critically important for the study of the
Na/H antiporter in cells from IDDM patients because elevated
glucose concentrations have been recently shown to increase
vascular Na/H antiporter activity [39] and may increase cellular
proliferation as well [40]. A recent study by Ng et al [34] made use
of Epstein-Barr virus-transformed lymphoblasts from IDDM pa-
tients as a way of developing an immortal cell culture model to
examine the mechanisms leading to activation of the Na
antiporter in IDDM patients who develop nephropathy. Na/H
antiporter activity was found to be increased only in cells from
IDDM patients with nephropathy. However, a difference in the
proliferation rate between cells from the three groups of subjects
was not found in this study [34]. The inability to detect differences
in the growth rates of these cells may be due to phenotypic
changes related to the immortalization process. Thus, the useful-
ness of this otherwise convenient in vitro model, in our opinion,
may be incomplete.
This study, as did previous studies that reported data on
Na!H antiporter activity in cells from IDDM patients [11, 12,
34], documented important clinical differences between the two
subgroups of IDDM patients in addition to the mere presence or
absence of nephropathy. These included the presence of hyper-
tension in most patients with nephropathy, their lower creatininc
clearance and their poorer glycemic control (Table 1). The
modest reduction in creatinine clearance in our patients, however,
makes it unlikely to be a factor independent of the variable under
study (that is, the presence of renal involvement in diabetes).
Glycemic control might have played a role if one postulates a
"memory" effect which is retained in vitro after several passages in
culture and while cells are kept in a media with a glucose
concentration identical to that of cells from controls. We believe
that the possibility of an effect secondary to previous lack of
glycemic control on either Na/H antiporter activity or DNA
synthesis is unlikely but cannot be completely excluded.
In immortalized lymphoblasts from individuals with essential
hypertension overactivity of the Nat/H I antiporter and increased
[3H] thymidine incorporation, have both been described [41]. This
raises the important question of whether these alterations are
unique to IDDM patients with nephropathy or simply reflect the
associated hypertension [42]. No differences in systemic blood
pressure were detectable between the two subgroups of IDDM
patients but in the subgroup with nephropathy most patients were
receiving antihypertensive therapy.
It should also be noted that both enhanced Na/H4 antiporter
activity and enhanced DNA synthesis have been described in
cultured vascular smooth muscle cells from the spontaneously
hypertensive rat [20, 281. However, in the DahI rat model of
salt-sensitive hypertension, Na/H antiporter activity is not
increased [43, 44]. These alterations, therefore, seem to be
genetically pre-determined, and not a consequence of hyperten-
sion per se. Whether in patients with IDDM these alterations
reflect a predisposition to hypertension or are predictive for
diabetic ncphropathy will require additional studies in IDDM
patients who have not developed either hypertension or incipient
nephropathy and who are followed longitudinally until the devel-
opment of nephropathy. The data overlap between IDDM pa-
tients with nephropathy and without (Figs. 3 and 5) suggest that it
may be premature to utilize assays of Na /H activity and cell
growth for clinical purposes at this time.
In summary, cultured skin fibroblasts from IDDM patients
display an abnormal growth phenotype characterized by cell
hyperplasia and this is associated with overactivity of the Na a/H'
antiporter under serum-stimulated conditions. These alterations
are more pronounced in cells from IDDM patients who had
developed overt nephropathy than in those who have not. It is
unlikely that early renal insufficiency in IDDM patients is respon-
sible for the observed alterations in cultured skin fibroblasts.
Rather, the cellular derangements expressed in cultured skin
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fibroblasts likely reflect glomerular mesangial abnormalities and
possibly the widespread vasculopathy that eventually afflicts most
IDDM patients with nephropathy. Finally, the studies using EIPA
to inhibit the Na/H antiporter demonstrate that overactivity of
this plasma membrane transporter is not an absolute requirement
for the expression of the abnormal growth phenotype observed in
cultured skin fibroblasts from IDDM patients with nephropathy.
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